RITTER PHARMACEUTICALS, INC. (NASDAQ:RTTR) Files An 8-K Other Events

RITTER PHARMACEUTICALS, INC. (NASDAQ:RTTR) Files An 8-K Other Events
Item 8.01 Other Events.

Story continues below

On March 5, 2019, Ritter Pharmaceuticals, Inc. issued a press release announcing that it has completed enrollment in its first pivotal Phase 3 clincal trial of RP-G28 for the potential treatment of lactose intolerance. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press Release dated March 5, 2019, entitled Ritter Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance

RITTER PHARMACEUTICALS INC Exhibit
EX-99.1 2 ex99-1.htm   Exhibit 99.1   Ritter Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance   Top-line Data Readout Expected in early Q4 2019   LOS ANGELES (March 5,…
To view the full exhibit click here

About RITTER PHARMACEUTICALS, INC. (NASDAQ:RTTR)

Ritter Pharmaceuticals, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health. The Company’s compound, RP-G28, is under development for the treatment of lactose intolerance. The Company has completed a Phase IIa clinical trial of its product candidate, RP-G28, an orally administered oligosaccharide. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. The Company has not generated any revenues.

An ad to help with our costs